H.C. Wainwright raised the firm’s price target on Prothena (PRTA) to $30 from $20 and keeps a Buy rating on the shares. The firm believes the market is overlooking the company’s two partnered Phase 3 programs and a partnered Phase 2 asset with blockbuster potential.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: